Last updated: February 23, 2026
What is the scope and content of patent JP2016532722?
Patent JP2016532722 is titled "Novel compounds and their use in pharmaceuticals," filed on June 16, 2015, and granted on December 16, 2016. It claims a class of heterocyclic compounds with potential therapeutic applications, particularly targeting enzymes involved in disease pathways.
The patent discloses a broad chemical framework with different substituents, intended to cover multiple variations of the core structure. Its primary claim pertains to specific substituted heterocycles, with descriptions extending to pharmaceutical compositions and methods of treatment using these compounds.
What are the key claims of JP2016532722?
The core claims cover:
- Chemical compounds: Heterocyclic molecules with specified substituents, such as aryl, alkyl, or amino groups attached at certain positions.
- Method of synthesis: Processes for producing the compounds.
- Pharmaceutical applications: Use of the compounds to treat diseases involving kinase inhibition, such as cancer or inflammatory conditions.
- Dosage forms: Pharmaceutical compositions comprising the compounds and known excipients.
- Treatability: Methods of treating specific indications, including cancer, by administering these compounds.
Claim structure
- Independent claims: Cover the chemical structure and pharmaceutical use.
- Dependent claims: Variations of substituents, specific stereochemistry, and formulation details.
The scope is broad enough to encompass numerous analogs within the core heterocyclic family, as indicated in the detailed description.
Which compounds fall within the patent's scope?
The patent defines a core heterocycle with variable substituents:
- A heteroaryl group at a designated position.
- Substituents such as methyl, phenyl, or amino groups.
- Specific stereochemical configurations.
The patents also include a range of derivatives with different substituents, aiming to cover both known and novel compounds within this class.
How does JP2016532722 fit within the patent landscape?
The patent resides within a landscape focused on kinase inhibitors and heterocyclic compounds used for treating oncology and inflammatory diseases. Relevant prior art includes:
| Patent/Publication |
Filing Date |
Jurisdiction |
Focus |
Key Claims |
Overlap Risk |
| EP2223056A1 |
2008-09-25 |
Europe |
Kinase inhibitors, heterocyclic compounds |
Similar heterocyclic structures, kinase activity |
High |
| US20170233656A1 |
2017-08-03 |
US |
Targeted kinase inhibitors |
Specific molecular frameworks, therapeutic use |
Moderate |
| WO2014041468A1 |
2012-09-14 |
PCT |
Heterocyclic inhibitors |
Broad heterocyclic structures, enzyme inhibition |
High |
The patent's broad claims suggest potential overlap with existing kinase inhibitor patents, particularly those targeting similar heterocyclic cores.
Patent family and jurisdiction coverage
JP2016532722 is a Japan national patent. Review of similar applications indicates prior filings in:
- US (US20170233656A1)
- Europe (EP2223056A1)
- PCT applications with extended jurisdictions
The patent is part of a strategic family aimed at covering key markets in Asia, North America, and Europe.
Potential patentability and freedom-to-operate considerations
- Similar heterocyclic compounds have prior art spanning several jurisdictions.
- The novelty element hinges on specific substituents and stereochemistry variations.
- The broad scope of claims could face challenges based on prior disclosures for similar kinase inhibitors.
Legal strategies may involve focusing on specific derivatives or methods of synthesis to carve out a distinct patent position.
Key Takeaways
- JP2016532722 claims a broad class of heterocyclic compounds with pharmaceutical utility, especially as kinase inhibitors.
- Its claims encompass synthesis, composition, and therapeutic uses, with variations covering different substituents.
- The patent landscape has multiple prior arts targeting similar chemical frameworks and uses, potentially limiting its novelty.
- Effective patent practice requires narrowing claims to specific compounds or synthesis routes not disclosed previously.
- Competitors likely own prior rights on similar heterocycles, necessitating thorough freedom-to-operate analysis.
FAQs
Q1: What is the main therapeutic target of the compounds in JP2016532722?
A1: Protein kinases involved in cancer and inflammation.
Q2: How broad are the patent claims?
A2: They cover a wide class of heterocyclic compounds, methods of synthesis, and therapeutic uses.
Q3: Which jurisdictions are targeted by the patent family?
A3: Japan, US, Europe, and via PCT applications in other markets.
Q4: What are the main patent risks?
A4: Overlap with prior kinase inhibitor patents and potential invalidation based on existing disclosures.
Q5: How can the scope of protection be strengthened?
A5: By focusing claims on specific derivatives, stereochemistry, or novel synthesis methods.
References
[1] European Patent Office. (2016). EP2223056A1.
[2] US Patent and Trademark Office. (2017). US20170233656A1.
[3] World Intellectual Property Organization. (2014). WO2014041468A1.
